For decades, Alzheimer's disease research has focused on amyloid as the primary pathogenic agent. This focus has driven the development of numerous amyloid‐targeting therapies; however, with one possible exception, none of these therapies have been effective in preventing or delaying cognitive decline in patients, and there are no approved disease‐modifying agents. It is becoming more apparent that alternative drug targets are needed to address this complex disease. An increased understanding of Alzheimer's disease pathology has highlighted the need to target the appropriate disease pathology at the appropriate time in the disease course. Preclinical and early clinical studies have focused on targets, including inflammation, tau, vascular health, and the microbiome. This report summarizes the presentations from a New York Academy of Sciences' one‐day symposium entitled “Alzheimer's Disease Therapeutics: Alternatives to Amyloid,” held on November 20, 2019.

中文翻译：

---

阿尔茨海默病治疗中淀粉样蛋白的替代品——研讨会报告

几十年来，阿尔茨海默病的研究一直集中在淀粉样蛋白作为主要致病因子。这一重点推动了众多淀粉样蛋白靶向疗法的发展；然而，除了一个可能的例外，这些疗法都不能有效地预防或延缓患者的认知能力下降，也没有批准的疾病缓解剂。越来越明显的是，需要替代药物靶点来解决这种复杂的疾病。对阿尔茨海默病病理学的深入了解突出了在疾病过程中的适当时间针对适当的疾病病理学的必要性。临床前和早期临床研究的重点是目标，包括炎症、tau、血管健康和微生物组。